Idiopathic Hypersomnia

Tomas Thorne

Basic

Last Updated: February 20, 2023

Idiopathic Hypersomnia

Research Based

ResearchPeptides.org follows the strictest sourcing guidelines in the health and nootropics industry. Our focus is to exclusively link to peer-reviewed studies found on respected websites, like PubMed. We focus on finding the most accurate information from the scientific source.

Our goal is to provide you with the most scientifically accurate, unbiased, and comprehensive information regarding all research peptides and SARMs.

All of our content is written by people with a strong science background, including medical researchers.

Our content is continually monitored by an internal peer-review process to ensure accuracy. We strive to never have a piece of inaccurate information on this website.

If you feel that any of our content is inaccurate or out-of-date, please contact us at: [email protected]

ABSTRACT

In contrast to narcolepsy and the Kleine-Levin syndrome, idiopathic hypersomnia is a recently described sleep disorder. Absence of associated clinical features such as cataplexy or megaphagia and characteristic polysomnographic features such as sleep-onset REM episodes render positive diagnosis more uncertain in idiopathic hypersomnia than in the fwo former conditions. Consequently there has been an unfortunate tendency to label all difficult to classify cases of excessive daytime sleepiness as idiopathic hypersomnia. At present due to the description of new disorders such as upper airway resistance syndrome, narcolepsy without cataplexy, delayed sleep phase syndrome, all of which were formerly confused with idiopathic hypersomnia and the clear identification of a “polysymptomatic” or “classic” form of idiopathic hypersomnia, the limits of the disorder become more precise. Still there are a number of cases of isolated excessive daytime sleepiness with no prolonged night sleep, no difficulty waking up, which lay between narcolepsy and genuine idiopathic hypersomnia. Thus there is a definite need to further develop laboratory investigations to help identify and classify these cases. Moreover pathophysiology and pathogenesis are still in their infancy and efforts have to be pursued in this direction. Treatment has not made consistent progress except for the use of a new wake promoting compound, modafinil, which has not yet been evaluated in controlled studies.

References

Table of Contents
    Add a header to begin generating the table of contents